{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:49:02Z","timestamp":1789159742888,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) reactivation in critically ill populations is associated with adverse outcomes. This study aimed to develop and validate an interpretable machine learning model to predict CMV reactivation within 28 days of ICU admission in sepsis patients, providing a risk stratification tool to optimize clinical management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study was conducted using data from intensive care unit (ICU) patients meeting SEPSIS-3 criteria. Key clinical variables, including acute physiology and chronic health evaluation \u2161(APACHE \u2161score), CMV IgG titer, CD4\n                      <jats:sup>+<\/jats:sup>\n                      lymphocyte count, and corticosteroid use duration, were selected through univariate logistic regression. Seven machine learning models were developed, with the gradient boosting machine (GBM) demonstrating superior performance. Model interpretability was enhanced using Shapley Additive Explanations (SHAP) to identify critical predictors and visualize feature contributions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 221 patients, 19.0% experienced CMV reactivation. The test set AUC values for GBM, logistic regression (LR), neural network (NN), support vector machine (SVM), random forest (RF), adaptive boosting (AdaBoost) and k-nearest neighbors (KNN) models were recorded as 0.761, 0.684, 0.673, 0.659, 0.65, 0.624, and 0.623, respectively. GBM model achieved the highest AUC in the test set, with robust calibration and net benefit of the GBM model in the test set exceeded that of the other models at threshold probabilities ranging from 10% to 60%. SHAP analysis identified the APACHE II score, corticosteroid use, CMV IgG levels, and CD4\u2009+\u2009lymphocyte count as the top four important predictors. Kaplan-Meier curves demonstrated significant stratification between high- and low-risk groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This interpretable machine learning model provides accurate CMV reactivation prediction and clear insights into contributing factors. It has the potential to enhance early risk stratification and guide targeted management strategies for sepsis patients in ICU settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12154-0","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:11:52Z","timestamp":1766412712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk stratification for CMV reactivation in sepsis patients: development of an interpretable machine learning model"],"prefix":"10.1186","volume":"25","author":[{"given":"Chengcheng","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"10","key":"12154_CR1","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/09540121.2018.1446071","volume":"30","author":"IB Thurston","year":"2018","unstructured":"Thurston IB, et al. Resilience as a moderator between syndemics and depression in mothers living with HIV. AIDS Care. 2018;30(10):1257\u201364.","journal-title":"AIDS Care"},{"issue":"2","key":"12154_CR2","doi-asserted-by":"publisher","first-page":"e98819","DOI":"10.1371\/journal.pone.0098819","volume":"9","author":"AH Walton","year":"2014","unstructured":"Walton AH, et al. Reactivation of multiple viruses in patients with sepsis. PLoS ONE. 2014;9(2):e98819.","journal-title":"PLoS ONE"},{"issue":"8","key":"12154_CR3","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1097\/CCM.0b013e3181a3aa43","volume":"37","author":"AC Kalil","year":"2009","unstructured":"Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med. 2009;37(8):2350\u20138.","journal-title":"Crit Care Med"},{"issue":"2","key":"12154_CR4","doi-asserted-by":"publisher","first-page":"ofx029","DOI":"10.1093\/ofid\/ofx029","volume":"4","author":"P Lachance","year":"2017","unstructured":"Lachance P, et al. Association between cytomegalovirus reactivation and clinical outcomes in immunocompetent critically ill patients: A systematic review and Meta-Analysis. Open Forum Infect Dis. 2017;4(2):ofx029.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"12154_CR5","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/cc7875","volume":"13","author":"R Osawa","year":"2009","unstructured":"Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009;13(3):R68.","journal-title":"Crit Care"},{"issue":"4","key":"12154_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/jama.300.4.413","volume":"300","author":"AP Limaye","year":"2008","unstructured":"Limaye AP, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300(4):413\u201322.","journal-title":"JAMA"},{"issue":"2","key":"12154_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40121-022-00746-1","volume":"12","author":"CN Kotton","year":"2023","unstructured":"Kotton CN, Kamar N. New insights on CMV management in solid organ transplant patients: Prevention, Treatment, and management of Resistant\/Refractory disease. Infect Dis Ther. 2023;12(2):333\u201342.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"12154_CR8","doi-asserted-by":"publisher","first-page":"e240383","DOI":"10.1001\/jamanetworkopen.2024.0383","volume":"7","author":"SS Cabler","year":"2024","unstructured":"Cabler SS, et al. Viral dnaemia and DNA virus seropositivity and mortality in pediatric sepsis. JAMA Netw Open. 2024;7(2):e240383.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"12154_CR9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/cid\/ciad708","volume":"78","author":"E Kampouri","year":"2024","unstructured":"Kampouri E, et al. Cytomegalovirus (CMV) reactivation and CMV-Specific Cell-Mediated immunity after chimeric antigen receptor T-Cell therapy. Clin Infect Dis. 2024;78(4):1022\u201332.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"12154_CR10","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/cid\/civ561","volume":"61","author":"A Saldan","year":"2015","unstructured":"Saldan A, et al. Strong Cell-Mediated immune response to human cytomegalovirus is associated with increased risk of fetal infection in primarily infected pregnant women. Clin Infect Dis. 2015;61(8):1228\u201334.","journal-title":"Clin Infect Dis"},{"key":"12154_CR11","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, et al. TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.","journal-title":"BMJ"},{"issue":"10","key":"12154_CR12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/ajh.26671","volume":"97","author":"L Eisenberg","year":"2022","unstructured":"Eisenberg L, et al. Time-dependent prediction of mortality and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation using machine learning. Am J Hematol. 2022;97(10):1309\u201323.","journal-title":"Am J Hematol"},{"key":"12154_CR13","unstructured":"Lundberg S. A unified approach to interpreting model predictions. arXiv preprint arXiv:1705.07874, 2017."},{"issue":"8","key":"12154_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"4","key":"12154_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s11357-011-9205-9","volume":"33","author":"SX Leng","year":"2011","unstructured":"Leng SX, et al. Relationship between cytomegalovirus (CMV) IgG serology, detectable CMV DNA in peripheral monocytes, and CMV pp65(495\u2013503)-specific CD8\u2009+\u2009T cells in older adults. Age (Dordr). 2011;33(4):607\u201314.","journal-title":"Age (Dordr)"},{"issue":"5","key":"12154_CR16","doi-asserted-by":"publisher","first-page":"e2212930","DOI":"10.1001\/jamanetworkopen.2022.12930","volume":"5","author":"H Deng","year":"2022","unstructured":"Deng H, et al. Development and validation of an explainable machine learning model for major complications after cytoreductive surgery. JAMA Netw Open. 2022;5(5):e2212930.","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"12154_CR17","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1093\/infdis\/jiz638","volume":"221","author":"H Imlay","year":"2020","unstructured":"Imlay H, Limaye AP. Current Understanding of cytomegalovirus reactivation in critical illness. J Infect Dis. 2020;221(Suppl 1):S94\u2013102.","journal-title":"J Infect Dis"},{"issue":"1","key":"12154_CR18","doi-asserted-by":"publisher","first-page":"9016","DOI":"10.1038\/s41598-019-45390-x","volume":"9","author":"TF Silva","year":"2019","unstructured":"Silva TF, et al. Reactivation of cytomegalovirus increases nitric oxide and IL-10 levels in sepsis and is associated with changes in renal parameters and worse clinical outcome. Sci Rep. 2019;9(1):9016.","journal-title":"Sci Rep"},{"issue":"1","key":"12154_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1186\/s13054-023-04713-1","volume":"27","author":"M Unterberg","year":"2023","unstructured":"Unterberg M, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis. Crit Care. 2023;27(1):417.","journal-title":"Crit Care"},{"issue":"2","key":"12154_CR20","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/cc10069","volume":"15","author":"A Heininger","year":"2011","unstructured":"Heininger A, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care. 2011;15(2):R77.","journal-title":"Crit Care"},{"issue":"12","key":"12154_CR21","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/infdis\/jiaa697","volume":"223","author":"H Imlay","year":"2021","unstructured":"Imlay H, et al. Risk factors for cytomegalovirus reactivation and association with outcomes in critically ill adults with sepsis: A pooled analysis of prospective studies. J Infect Dis. 2021;223(12):2108\u201312.","journal-title":"J Infect Dis"},{"issue":"6","key":"12154_CR22","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00134-022-06716-y","volume":"48","author":"I Gatto","year":"2022","unstructured":"Gatto I, et al. Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. Intensive Care Med. 2022;48(6):706\u201313.","journal-title":"Intensive Care Med"},{"issue":"1","key":"12154_CR23","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1186\/s12879-021-06698-0","volume":"21","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, et al. Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study. BMC Infect Dis. 2021;21(1):1026.","journal-title":"BMC Infect Dis"},{"key":"12154_CR24","doi-asserted-by":"crossref","unstructured":"Zangger N, Oderbolz J, Oxenius A. CD4 T Cell-mediated immune control of cytomegalovirus infection in murine salivary glands. Pathogens, 2021;10(12).","DOI":"10.3390\/pathogens10121531"},{"issue":"3","key":"12154_CR25","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1128\/jvi.68.3.1597-1604.1994","volume":"68","author":"J Taylor-Wiedeman","year":"1994","unstructured":"Taylor-Wiedeman J, Sissons P, Sinclair J. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J Virol. 1994;68(3):1597\u2013604.","journal-title":"J Virol"},{"issue":"6","key":"12154_CR26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41409-023-01944-2","volume":"58","author":"KA Eberhardt","year":"2023","unstructured":"Eberhardt KA, et al. CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transpl. 2023;58(6):639\u201346.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"12154_CR27","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.bbmt.2020.07.034","volume":"26","author":"LJ Arcuri","year":"2020","unstructured":"Arcuri LJ, et al. Impact of Anti-CMV IgG titers and CD34 count prior to hematopoietic stem cell transplantation from alternative donors on CMV reactivation. Biol Blood Marrow Transpl. 2020;26(11):e275\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"12154_CR28","first-page":"683","volume":"27","author":"S Kawamura","year":"2021","unstructured":"Kawamura S, et al. Prediction of cytomegalovirus reactivation by recipient cytomegalovirus-IgG titer before allogeneic hematopoietic stem cell transplantation. Transpl Cell Ther. 2021;27(8):683. e1-683 e7.","journal-title":"Transpl Cell Ther"},{"key":"12154_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12979-015-0056-6","volume":"13","author":"HM Parry","year":"2016","unstructured":"Parry HM, et al. Cytomegalovirus viral load within blood increases markedly in healthy people over the age of 70 years. Immun Ageing. 2016;13:1.","journal-title":"Immun Ageing"},{"key":"12154_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jcv.2018.09.019","volume":"108","author":"G Galitska","year":"2018","unstructured":"Galitska G, et al. Biological relevance of cytomegalovirus genetic variability in congenitally and postnatally infected children. J Clin Virol. 2018;108:132\u201340.","journal-title":"J Clin Virol"},{"key":"12154_CR31","doi-asserted-by":"publisher","first-page":"102185","DOI":"10.1016\/j.coi.2022.102185","volume":"77","author":"N Zangger","year":"2022","unstructured":"Zangger N, Oxenius A. T cell immunity to cytomegalovirus infection. Curr Opin Immunol. 2022;77:102185.","journal-title":"Curr Opin Immunol"},{"key":"12154_CR32","doi-asserted-by":"crossref","unstructured":"Pickering H et al. NK and CD8\u2009+\u2009T cell phenotypes predict onset and control of CMV viremia after kidney transplant. JCI Insight, 2021;6(21).","DOI":"10.1172\/jci.insight.153175"},{"issue":"11","key":"12154_CR33","doi-asserted-by":"publisher","first-page":"e3634","DOI":"10.1371\/journal.pone.0003634","volume":"3","author":"T Widmann","year":"2008","unstructured":"Widmann T, et al. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS ONE. 2008;3(11):e3634.","journal-title":"PLoS ONE"},{"issue":"1","key":"12154_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12967-016-0988-4","volume":"14","author":"J Drylewicz","year":"2016","unstructured":"Drylewicz J, et al. Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation. J Transl Med. 2016;14(1):230.","journal-title":"J Transl Med"},{"key":"12154_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fimmu.2017.00019","volume":"8","author":"JA Juno","year":"2017","unstructured":"Juno JA, et al. Cytotoxic CD4 T Cells-Friend or foe during viral infection? Front Immunol. 2017;8:19.","journal-title":"Front Immunol"},{"key":"12154_CR36","doi-asserted-by":"publisher","first-page":"779961","DOI":"10.3389\/fimmu.2021.779961","volume":"12","author":"M Lyu","year":"2021","unstructured":"Lyu M, et al. Dissecting the landscape of activated CMV-Stimulated CD4\u2009+\u2009T cells in humans by linking Single-Cell RNA-Seq with T-Cell receptor sequencing. Front Immunol. 2021;12:779961.","journal-title":"Front Immunol"},{"issue":"6","key":"12154_CR37","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.celrep.2015.09.082","volume":"13","author":"JT Thom","year":"2015","unstructured":"Thom JT, et al. The salivary gland acts as a sink for Tissue-Resident memory CD8(+) T Cells, facilitating protection from local cytomegalovirus infection. Cell Rep. 2015;13(6):1125\u201336.","journal-title":"Cell Rep"},{"issue":"19","key":"12154_CR38","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood.2019000956","volume":"135","author":"H Einsele","year":"2020","unstructured":"Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135(19):1619\u201329.","journal-title":"Blood"},{"issue":"17","key":"12154_CR39","first-page":"2062","volume":"141","author":"SS Dadwal","year":"2023","unstructured":"Dadwal SS, Papanicolaou GA, Boeckh M. How I prevent viral reactivation in high-risk patients. Blood. 2023;141(17):2062\u201374.","journal-title":"Blood"},{"issue":"4","key":"12154_CR40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/cid\/cix793","volume":"66","author":"Y Natori","year":"2018","unstructured":"Natori Y, et al. Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: A systematic review and Meta-analysis. Clin Infect Dis. 2018;66(4):617\u201331.","journal-title":"Clin Infect Dis"},{"key":"12154_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fmed.2020.00188","volume":"7","author":"J Schildermans","year":"2020","unstructured":"Schildermans J, De Vlieger G. Cytomegalovirus: A Troll in the ICU? Overview of the literature and perspectives for the future. Front Med (Lausanne). 2020;7:188.","journal-title":"Front Med (Lausanne)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12154-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12154-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12154-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:35:11Z","timestamp":1781624111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12154-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12154"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12154-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Ruijin Hospital, Shanghai JiaoTong University School of Medicine (KY2024-515), and was granted an exemption from informed consent. It was registered in the Chinese Clinical Trial Registry (ChiCTR2500095277). This study was conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1729"}}